News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nymox Pharmaceutical (NYMX) NX-1207 BPH and Prostate Cancer Symposium at American Urological Association Annual Meeting May 5 in San Diego


4/11/2013 2:39:50 PM

HASBROUCK HEIGHTS, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for Prostate Cancer. The symposium will be held during the 2013 Annual Meeting of the American Urological Association in San Diego CA 3:00 p.m. May 5 in the San Diego Convention Center.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES